News

Cupron® Performance Additives Unveils Groundbreaking “Clear” Liquid Copper Platform for Sustainable Microbial Control Applications

Cupron Performance Additives (Cupron) today announced the launch of Cupron Clear™ — a revolutionary new liquid microbial copper platform. Cupron Clear™ is a transparent, stable, and highly efficacious liquid form of copper, designed for broad use across polymers and liquids. This new breakthrough delivers unmatched microbial control while exceeding modern standards for sustainability, economics, and safety.

Cupron Clear™ reinvents the chemistry of copper-based additives for liquid products, delivering over a hundred times the effectiveness of conventional copper solutions. With its innovative clear liquid format, Cupron Clear™ out-performs incumbent additives such as QUATs and Isothiazolinones, many of which are facing growing regulatory pressure. Cupron Clear™ sets a new standard for broad-spectrum efficacy against microorganisms. This next-generation technology provides end market and downstream users with a more sustainable, versatile, and high-performing copper-based biocide than ever before.

“This new liquid copper platform addresses the frustrations for so many different industries and dramatically expands the applications that can enjoy the benefits of Cupron innovations,” said Chris Andrews, CEO of Cupron. “It’s the direct result of focused R&D and our belief that economic, safer, sustainable technologies should replace legacy materials that no longer meet regulatory or performance standards.”

Representing a major leap forward in copper-based technologies, Cupron Clear™ is a first-to-market solution for personal care, hygiene, building & construction, textiles, plastics, paints and other coatings, adhesives, sealants, elastomers (C.A.S.E.) markets in need of the highest-performing form of cuprous copper in a colorless, liquid format.

“With the addition of Cupron Clear™ to the company’s product portfolio, we can now offer our partners unparalleled flexibility in manufacturing and application with a comprehensive suite of platforms across solid, dispersion and solution-based applications,” Andrews added.

In addition to securing patents and intellectual property rights across composition, process, and applications of Cupron Clear™, Cupron is already in discussion with global partners and distributors to deploy it across core markets.

Read more here.

Recent News

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza